Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites

Viral latency of human immunodeficiency virus type 1 (HIV-1) has become a major hurdle to a cure in the highly effective antiretroviral therapy (ART) era. The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system has successfully been demonstrated to excise or inactivate int...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Cheng-Han, Allen, Alexander G., Atkins, Andrew J., Sullivan, Neil T., Homan, Greg, Costello, Robert, Madrid, Rebekah, Nonnemacher, Michael R., Dampier, Will, Wigdahl, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452136/
https://www.ncbi.nlm.nih.gov/pubmed/32818921
http://dx.doi.org/10.1016/j.omtn.2020.07.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452136/
https://www.ncbi.nlm.nih.gov/pubmed/32818921
http://dx.doi.org/10.1016/j.omtn.2020.07.016

Ejemplares similares